ゼリア新薬工業（4559）のセグメントごとの売上高・利益等
セグメント通期
- 【有報】
- セグメント情報等、連結財務諸表
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
|---|---|---|---|---|
| 売上高 | 2013/03 | 319億 | 212億 | 217百万 |
| 2014/03 | 364億 +14.1% | 254億 +19.9% | 177百万 -18.7% | |
| 2015/03 | 338億 -7.3% | 271億 +6.7% | 158百万 -10.6% | |
| 2016/03 | 339億 +0.4% | 284億 +4.9% | 153百万 -3.4% | |
| 2017/03 | 344億 +1.6% | 303億 +6.5% | 142百万 -6.8% | |
| 2018/03 | 346億 +0.4% | 298億 -1.5% | 154百万 +8.5% | |
| 2019/03 | 318億 -8% | 298億 ±0% | 160百万 +3.6% | |
| 2020/03 | 318億 -0.2% | 285億 -4.5% | 155百万 -2.9% | |
| 2021/03 | 300億 -5.7% | 226億 -20.5% | 157百万 +1.3% | |
| 2022/03 | 370億 +23.6% | 224億 -1.2% | 157百万 -0.3% | |
| 2023/03 | 431億 +16.6% | 251億 +12.1% | 152百万 -2.8% | |
| 2024/03 | 496億 +14.9% | 260億 +3.6% | 155百万 +1.6% | |
| 2025/03 | 590億 +19% | 282億 +8.4% | 161百万 +3.8% | |
| 2026/03 | - | - | 151百万 -6.1% | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| 営業利益 | 2013/03 | 65.4億 | 28.2億 | 191百万 |
| 2014/03 | 67.6億 +3.5% | 51.8億 +83.6% | 173百万 -9.4% | |
| 2015/03 | 19.3億 -71.4% | 58.4億 +12.8% | 234百万 +35.2% | |
| 2016/03 | 30.1億 +55.6% | 66.3億 +13.6% | 240百万 +2.8% | |
| 2017/03 | 17.2億 -42.9% | 79.8億 +20.3% | 246百万 +2.3% | |
| 2018/03 | 25.8億 +50% | 71.5億 -10.4% | 252百万 +2.3% | |
| 2019/03 | 19億 -26.4% | 65.1億 -8.9% | 240百万 -4.8% | |
| 2020/03 | 25.5億 +34.5% | 61.9億 -4.9% | 249百万 +3.8% | |
| 2021/03 | 35億 +37.1% | 46.9億 -24.2% | 262百万 +5.5% | |
| 2022/03 | 69.1億 +97.7% | 40.4億 -14% | 261百万 -0.5% | |
| 2023/03 | 87.2億 +26.2% | 49.7億 +23.1% | 242百万 -7.2% | |
| 2024/03 | 92.5億 +6% | 52.6億 +5.8% | 251百万 +3.7% | |
| 2025/03 | 108億 +16.5% | 64億 +21.6% | 244百万 -3% | |
| 2026/03 | - | - | 201百万 -17.5% | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| 営業利益率 | 2013/03 | 20.5% | 13.3% | 87.9% |
| 2014/03 | 18.6% -1.9% | 20.4% +7.1% | 97.9% +10% | |
| 2015/03 | 5.7% -12.9% | 21.5% +1.1% | 148.1% +50.2% | |
| 2016/03 | 8.9% +3.2% | 23.3% +1.8% | 157.6% +9.5% | |
| 2017/03 | 5% -3.9% | 26.4% +3.1% | 173.1% +15.5% | |
| 2018/03 | 7.4% +2.4% | 24% -2.4% | 163.3% -9.8% | |
| 2019/03 | 6% -1.4% | 21.8% -2.2% | 150.1% -13.2% | |
| 2020/03 | 8% +2% | 21.7% -0.1% | 160.4% +10.3% | |
| 2021/03 | 11.7% +3.7% | 20.7% -1% | 167% +6.6% | |
| 2022/03 | 18.7% +7% | 18.1% -2.6% | 166.7% -0.3% | |
| 2023/03 | 20.2% +1.5% | 19.8% +1.7% | 159.1% -7.6% | |
| 2024/03 | 18.7% -1.5% | 20.2% +0.4% | 162.4% +3.3% | |
| 2025/03 | 18.3% -0.4% | 22.7% +2.5% | 151.7% -10.7% | |
| 2026/03 | - | - | 133.2% -18.5% | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| 研究開発費 | 2013/03 | - | - | - |
| 2014/03 | - | - | - | |
| 2015/03 | - | - | - | |
| 2016/03 | - | - | - | |
| 2017/03 | - | - | - | |
| 2018/03 | - | - | - | |
| 2019/03 | 62.5億 | 582百万 | - | |
| 2020/03 | 57.5億 -8% | 590百万 +1.4% | - | |
| 2021/03 | 48.3億 -16.1% | 584百万 -1% | - | |
| 2022/03 | 42.1億 -12.8% | 580百万 -0.7% | - | |
| 2023/03 | 27.7億 -34.1% | 683百万 +17.8% | - | |
| 2024/03 | 30.4億 +9.6% | 688百万 +0.7% | - | |
| 2025/03 | 33.9億 +11.5% | 718百万 +4.4% | - | |
| 2026/03 | - | - | - | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| 設備投資額 | 2013/03 | - | - | - |
| 2014/03 | - | - | - | |
| 2015/03 | - | - | - | |
| 2016/03 | - | - | - | |
| 2017/03 | - | - | - | |
| 2018/03 | - | - | - | |
| 2019/03 | 7.15億 | 313百万 | - | |
| 2020/03 | 2.12億 -70.3% | 185百万 -40.9% | - | |
| 2021/03 | 2.58億 +21.7% | 446百万 +141.1% | - | |
| 2022/03 | 3.68億 +42.6% | 455百万 +2% | - | |
| 2023/03 | 16.8億 +357.1% | 515百万 +13.2% | - | |
| 2024/03 | 16.1億 -4.4% | 782百万 +51.8% | - | |
| 2025/03 | 5.46億 -66% | 332百万 -57.5% | - | |
| 2026/03 | - | - | - | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| 固定資産増加額 | 2013/03 | 6.3億 | 4.88億 | 0.24百万 |
| 2014/03 | 10.5億 +67.3% | 4.45億 -8.9% | 17.9億 +999.99% | |
| 2015/03 | 11.3億 +7.1% | 7.2億 +61.9% | 0.01億 -100% | |
| 2016/03 | 275億 +999.99% | 10.3億 +42.6% | 4.02億 +999.99% | |
| 2017/03 | 21.9億 -92% | 23.7億 +130.6% | 0.39億 -90.3% | |
| 2018/03 | 5.9億 -73.1% | 2.23億 -90.6% | 0.2億 -48.1% | |
| 2019/03 | 10.3億 +74% | 3.31億 +48.6% | 0.13億 -35.1% | |
| 2020/03 | 30.4億 +196.4% | 2.65億 -20% | 0.41億 +213% | |
| 2021/03 | 139億 +355.7% | 4.83億 +82.3% | 0.12億 -69.9% | |
| 2022/03 | 6.42億 -95.4% | 5.63億 +16.6% | 0.39億 +210.4% | |
| 2023/03 | 22.1億 +245.2% | 5.56億 -1.2% | 0.82億 +113.6% | |
| 2024/03 | 27.3億 +23.1% | 8.29億 +49.1% | 0.36億 -56.8% | |
| 2025/03 | 19.7億 -27.6% | 3.75億 -54.7% | 0.76億 +115.2% | |
| 2026/03 | - | - | 0.37億 -52% | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| 従業員数 | 2013/03 | - | - | - |
| 2014/03 | - | - | - | |
| 2015/03 | - | - | - | |
| 2016/03 | - | - | - | |
| 2017/03 | - | - | - | |
| 2018/03 | - | - | - | |
| 2019/03 | 674 | 755 | 8 | |
| 2020/03 | 643 -4.6% | 737 -2.4% | 8 ±0% | |
| 2021/03 | 632 -1.7% | 771 +4.6% | 8 ±0% | |
| 2022/03 | 713 +12.8% | 746 -3.2% | 7 -12.5% | |
| 2023/03 | 701 -1.7% | 733 -1.7% | 7 ±0% | |
| 2024/03 | 729 +4% | 753 +2.7% | 7 ±0% | |
| 2025/03 | 742 +1.8% | 709 -5.8% | 7 ±0% | |
| 2026/03 | - | - | - | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| 平均臨時雇用人員 | 2013/03 | - | - | - |
| 2014/03 | - | - | - | |
| 2015/03 | - | - | - | |
| 2016/03 | - | - | - | |
| 2017/03 | - | - | - | |
| 2018/03 | - | - | - | |
| 2019/03 | 45 | 91 | - | |
| 2020/03 | 43 -4.4% | 91 ±0% | - | |
| 2021/03 | 46 +7% | 90 -1.1% | - | |
| 2022/03 | 51 +10.9% | 84 -6.7% | - | |
| 2023/03 | 51 ±0% | 92 +9.5% | - | |
| 2024/03 | 49 -3.9% | 101 +9.8% | - | |
| 2025/03 | 44 -10.2% | 101 ±0% | - | |
| 2026/03 | - | - | - | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| 資産 | 2013/03 | 293億 | 224億 | 42.5億 |
| 2014/03 | 344億 +17.5% | 251億 +12.3% | 50.2億 +18% | |
| 2015/03 | 358億 +4.1% | 241億 -4.1% | 48.9億 -2.5% | |
| 2016/03 | 617億 +72.1% | 241億 -0.1% | 52.2億 +6.7% | |
| 2017/03 | 570億 -7.6% | 267億 +10.9% | 51.9億 -0.5% | |
| 2018/03 | 551億 -3.3% | 271億 +1.4% | 51.4億 -1% | |
| 2019/03 | 516億 -6.5% | 271億 +0.1% | 51.1億 -0.7% | |
| 2020/03 | 517億 +0.2% | 244億 -9.8% | 50.8億 -0.6% | |
| 2021/03 | 647億 +25.2% | 274億 +12.1% | 50.8億 ±0% | |
| 2022/03 | 682億 +5.4% | 271億 -1% | 50.1億 -1.4% | |
| 2023/03 | 771億 +13.1% | 275億 +1.6% | 49.6億 -0.9% | |
| 2024/03 | 883億 +14.5% | 285億 +3.6% | 49.4億 -0.4% | |
| 2025/03 | 960億 +8.8% | 289億 +1.5% | 49億 -0.8% | |
| 2026/03 | - | - | 48.7億 -0.5% | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| 減損損失 | 2013/03 | - | 21百万 | - |
| 2014/03 | - | - | - | |
| 2015/03 | 273百万 | - | - | |
| 2016/03 | - | - | 144百万 | |
| 2017/03 | 319百万 | - | - | |
| 2018/03 | - | - | - | |
| 2019/03 | - | - | - | |
| 2020/03 | - | - | - | |
| 2021/03 | 33百万 | - | - | |
| 2022/03 | - | - | - | |
| 2023/03 | - | - | - | |
| 2024/03 | - | - | - | |
| 2025/03 | - | - | - | |
| 2026/03 | - | - | - | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| のれん | 2013/03 | 86.6億 | 28.5億 | - |
| 2014/03 | 81.4億 -6% | 41億 +43.8% | - | |
| 2015/03 | 76.3億 -6.3% | 39.1億 -4.7% | - | |
| 2016/03 | 71.9億 -5.7% | 29.5億 -24.5% | - | |
| 2017/03 | 66.6億 -7.3% | 25.8億 -12.7% | - | |
| 2018/03 | 61.4億 -7.9% | 25.8億 +0.1% | - | |
| 2019/03 | 55.8億 -9.1% | 22.8億 -11.5% | - | |
| 2020/03 | 50.4億 -9.7% | 20.4億 -10.4% | - | |
| 2021/03 | 45.2億 -10.2% | 19.1億 -6.7% | - | |
| 2022/03 | 40.2億 -11.1% | 18.1億 -5.1% | - | |
| 2023/03 | 35.7億 -11.2% | 17.3億 -4.3% | - | |
| 2024/03 | 28.5億 -20.3% | 14.2億 -18.1% | - | |
| 2025/03 | 23.5億 -17.3% | 12.7億 -10.5% | - | |
| 2026/03 | - | - | - | |
| 科目 | 年度 | 医療用医薬品事業 | コンシューマーヘルスケア事業 | その他 |
| のれん償却額 | 2013/03 | 517百万 | 145百万 | - |
| 2014/03 | 517百万 ±0% | 197百万 +36.4% | - | |
| 2015/03 | 517百万 ±0% | 231百万 +17.2% | - | |
| 2016/03 | 503百万 -2.7% | 187百万 -19% | - | |
| 2017/03 | 512百万 +1.8% | 176百万 -5.8% | - | |
| 2018/03 | 512百万 +0.1% | 185百万 +4.8% | - | |
| 2019/03 | 510百万 -0.5% | 191百万 +3.5% | - | |
| 2020/03 | 508百万 -0.4% | 181百万 -5.5% | - | |
| 2021/03 | 508百万 ±-0% | 180百万 -0.5% | - | |
| 2022/03 | 507百万 -0.2% | 193百万 +7.2% | - | |
| 2023/03 | 512百万 +1% | 205百万 +6.4% | - | |
| 2024/03 | 767百万 +49.9% | 447百万 +117.8% | - | |
| 2025/03 | 494百万 -35.7% | 218百万 -51.2% | - | |
| 2026/03 | - | - | - |
セグメント四半期
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
|---|---|---|---|---|---|---|
| 医療用医薬品事業 | ||||||
| 売上高 1Q2Q 3Q | 2014/03 | 98.2億 | 87.8億 | 94.2億 | 84.1億 | 364億 |
| 2015/03 | 82.8億 -15.6% | 86.3億 -1.7% | 80.7億 -14.3% | 87.7億 +4.4% | 338億 -7.3% | |
| 2016/03 | 80.5億 -2.7% | 85.5億 -0.9% | 89.3億 +10.5% | 83.7億 -4.6% | 339億 +0.4% | |
| 2017/03 | 94.1億 +16.9% | 83.7億 -2.1% | 80.4億 -9.9% | 86.1億 +2.8% | 344億 +1.6% | |
| 2018/03 | 89.6億 -4.8% | 89.4億 +6.8% | 87.6億 +9% | 79.3億 -7.9% | 346億 +0.4% | |
| 2019/03 | 81.3億 -9.2% | 80.7億 -9.7% | 78.4億 -10.5% | 77.9億 -1.7% | 318億 -8% | |
| 2020/03 | 80億 -1.7% | 77億 -4.6% | 79.4億 +1.2% | 81.4億 +4.5% | 318億 -0.2% | |
| 2021/03 | 75.5億 -5.6% | 69.1億 -10.2% | 79.9億 +0.7% | 75億 -7.9% | 300億 -5.7% | |
| 2022/03 | 82.6億 +9.4% | 97.4億 +40.9% | 95.3億 +19.3% | 94.8億 +26.4% | 370億 +23.6% | |
| 2023/03 | 103億 +24.5% | 112億 +15.3% | 109億 +14.7% | 107億 +13% | 431億 +16.6% | |
| 2024/03 | 119億 +16.2% | 120億 +6.5% | 136億 +24.9% | 120億 +12.3% | 496億 +14.9% | |
| 営業利益 1Q2Q 3Q | 2014/03 | 31.8億 | 12.9億 | 18.2億 | 4.69億 | 67.6億 |
| 2015/03 | 7.99億 -74.9% | 12.2億 -5.8% | 6.64億 -63.5% | -7.45億 赤字 | 19.3億 -71.4% | |
| 2016/03 | 6.26億 -21.6% | 10.1億 -16.5% | 10.5億 +58.3% | 3.17億 | 30.1億 +55.6% | |
| 2017/03 | 11.8億 +88% | 7.94億 -21.7% | -6.33億 赤字 | 3.79億 +19.5% | 17.2億 -42.9% | |
| 2018/03 | 0.6億 -94.9% | 15.5億 +95.4% | 14.1億 | -4.45億 赤字 | 25.8億 +50% | |
| 2019/03 | 13.7億 +999.99% | 3.61億 -76.7% | 0.55億 -96.1% | 1.12億 | 19億 -26.4% | |
| 2020/03 | 7.74億 -43.4% | -1.48億 赤字 | 12.8億 +999.99% | 6.42億 +474.1% | 25.5億 +34.5% | |
| 2021/03 | 12億 +54.8% | 3.99億 | 18.1億 +41.4% | 0.86億 -86.5% | 35億 +37.1% | |
| 2022/03 | 15.5億 +29.2% | 15.4億 +284.6% | 24.6億 +35.8% | 13.7億 +999.99% | 69.1億 +97.7% | |
| 2023/03 | 28.3億 +83.1% | 30.4億 +97.7% | 21.7億 -11.9% | 6.84億 -50% | 87.2億 +26.2% | |
| 2024/03 | 28.7億 +1.5% | 23.8億 -21.5% | 36.9億 +70.3% | 2.95億 -56.9% | 92.5億 +6% | |
| 営業利益率 | 2014/03 | 32.4% | 14.7% | 19.3% | 5.6% | 18.6% |
| 2015/03 | 9.6% -22.8% | 14.1% -0.6% | 8.2% -11.1% | -8.5% 赤字 | 5.7% -12.9% | |
| 2016/03 | 7.8% -1.8% | 11.9% -2.2% | 11.8% +3.6% | 3.8% | 8.9% +3.2% | |
| 2017/03 | 12.5% +4.7% | 9.5% -2.4% | -7.9% 赤字 | 4.4% +0.6% | 5% -3.9% | |
| 2018/03 | 0.7% -11.8% | 17.4% +7.9% | 16.1% | -5.6% 赤字 | 7.4% +2.4% | |
| 2019/03 | 16.8% +16.1% | 4.5% -12.9% | 0.7% -15.4% | 1.4% | 6% -1.4% | |
| 2020/03 | 9.7% -7.1% | -1.9% 赤字 | 16.2% +15.5% | 7.9% +6.5% | 8% +2% | |
| 2021/03 | 15.9% +6.2% | 5.8% | 22.7% +6.5% | 1.2% -6.7% | 11.7% +3.7% | |
| 2022/03 | 18.7% +2.8% | 15.8% +10% | 25.8% +3.1% | 14.4% +13.2% | 18.7% +7% | |
| 2023/03 | 27.5% +8.8% | 27.1% +11.3% | 19.8% -6% | 6.4% -8% | 20.2% +1.5% | |
| 2024/03 | 24.1% -3.4% | 19.9% -7.2% | 27.1% +7.3% | 2.5% -3.9% | 18.7% -1.5% | |
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
| コンシューマーヘルスケア事業 | ||||||
| 売上高 1Q2Q 3Q | 2014/03 | 54.7億 | 59.4億 | 72億 | 67.8億 | 254億 |
| 2015/03 | 64億 +17% | 67.5億 +13.5% | 75.3億 +4.7% | 64.2億 -5.4% | 271億 +6.7% | |
| 2016/03 | 66.3億 +3.6% | 70.3億 +4.2% | 77.5億 +2.8% | 70.2億 +9.3% | 284億 +4.9% | |
| 2017/03 | 70.4億 +6.2% | 74.2億 +5.6% | 86.5億 +11.7% | 71.6億 +2.1% | 303億 +6.5% | |
| 2018/03 | 69.8億 -0.9% | 74.6億 +0.6% | 84.3億 -2.6% | 69.6億 -2.9% | 298億 -1.5% | |
| 2019/03 | 70.9億 +1.7% | 71.2億 -4.7% | 88.4億 +4.9% | 67.9億 -2.4% | 298億 ±0% | |
| 2020/03 | 70.8億 -0.2% | 74.7億 +4.9% | 80.1億 -9.4% | 59.5億 -12.4% | 285億 -4.5% | |
| 2021/03 | 51.5億 -27.3% | 58.3億 -21.9% | 68.2億 -14.9% | 48.5億 -18.4% | 226億 -20.5% | |
| 2022/03 | 52.5億 +2% | 52.8億 -9.5% | 69.2億 +1.6% | 49.1億 +1.3% | 224億 -1.2% | |
| 2023/03 | 59.9億 +14% | 61.4億 +16.3% | 70.5億 +1.9% | 59億 +20.1% | 251億 +12.1% | |
| 2024/03 | 63.2億 +5.5% | 63.8億 +3.9% | 75.5億 +7.2% | 57.4億 -2.7% | 260億 +3.6% | |
| 営業利益 1Q2Q 3Q | 2014/03 | 9.13億 | 12.1億 | 13.4億 | 17.1億 | 51.8億 |
| 2015/03 | 12.3億 +34.7% | 14.1億 +16.3% | 16.6億 +23.4% | 15.4億 -9.7% | 58.4億 +12.8% | |
| 2016/03 | 17.4億 +41.7% | 12.6億 -10.4% | 19.2億 +15.7% | 17.1億 +11% | 66.3億 +13.6% | |
| 2017/03 | 18.9億 +8.6% | 18.4億 +46.1% | 23.9億 +24.8% | 18.5億 +8.2% | 79.8億 +20.3% | |
| 2018/03 | 17.7億 -6.7% | 15.1億 -18.1% | 19.3億 -19.4% | 19.5億 +5% | 71.5億 -10.4% | |
| 2019/03 | 14.8億 -16.2% | 11億 -27.5% | 22.1億 +14.8% | 17.3億 -11.4% | 65.1億 -8.9% | |
| 2020/03 | 17.7億 +19.9% | 17億 +54.9% | 15.2億 -31.1% | 12億 -30.6% | 61.9億 -4.9% | |
| 2021/03 | 10.6億 -40.2% | 12.9億 -23.9% | 16.9億 +10.8% | 6.52億 -45.5% | 46.9億 -24.2% | |
| 2022/03 | 9.86億 -7% | 9.91億 -23.3% | 15.3億 -9.3% | 5.29億 -18.9% | 40.4億 -14% | |
| 2023/03 | 13.5億 +36.6% | 11.1億 +11.9% | 15.5億 +1.3% | 9.64億 +82.2% | 49.7億 +23.1% | |
| 2024/03 | 13.7億 +1.5% | 11.6億 +4.6% | 16.6億 +6.8% | 10.8億 +11.6% | 52.6億 +5.8% | |
| 営業利益率 | 2014/03 | 16.7% | 20.4% | 18.7% | 25.2% | 20.4% |
| 2015/03 | 19.2% +2.5% | 20.9% +0.5% | 22% +3.3% | 24.1% -1.1% | 21.5% +1.1% | |
| 2016/03 | 26.3% +7.1% | 18% -2.9% | 24.7% +2.7% | 24.4% +0.3% | 23.3% +1.8% | |
| 2017/03 | 26.9% +0.6% | 24.9% +6.9% | 27.6% +2.9% | 25.9% +1.5% | 26.4% +3.1% | |
| 2018/03 | 25.3% -1.6% | 20.2% -4.7% | 22.8% -4.8% | 28% +2.1% | 24% -2.4% | |
| 2019/03 | 20.9% -4.4% | 15.4% -4.8% | 25% +2.2% | 25.4% -2.6% | 21.8% -2.2% | |
| 2020/03 | 25% +4.1% | 22.7% +7.3% | 19% -6% | 20.1% -5.3% | 21.7% -0.1% | |
| 2021/03 | 20.6% -4.4% | 22.1% -0.6% | 24.8% +5.8% | 13.4% -6.7% | 20.7% -1% | |
| 2022/03 | 18.8% -1.8% | 18.8% -3.3% | 22.1% -2.7% | 10.8% -2.6% | 18.1% -2.6% | |
| 2023/03 | 22.5% +3.7% | 18% -0.8% | 22% -0.1% | 16.3% +5.5% | 19.8% +1.7% | |
| 2024/03 | 21.6% -0.9% | 18.2% +0.2% | 21.9% -0.1% | 18.7% +2.4% | 20.2% +0.4% | |
| 科目 | 年度 | 1Q | 2Q | 3Q | 4Q | 通期 |
| その他 | ||||||
| 売上高 1Q2Q 3Q | 2014/03 | 57百万 | 40百万 | 44百万 | 36百万 | 177百万 |
| 2015/03 | 38百万 -33.7% | 42百万 +5.2% | 40百万 -9% | 39百万 +6.1% | 158百万 -10.6% | |
| 2016/03 | 41百万 +10.1% | 37百万 -10.8% | 40百万 +0.5% | 34百万 -12.7% | 153百万 -3.4% | |
| 2017/03 | 34百万 -18% | 36百万 -4.6% | 38百万 -6.5% | 35百万 +4% | 142百万 -6.8% | |
| 2018/03 | 37百万 +7.9% | 40百万 +12% | 40百万 +6.8% | 38百万 +7.2% | 154百万 +8.5% | |
| 2019/03 | 36百万 -0.5% | 41百万 +2.7% | 46百万 +14.4% | 36百万 -3.2% | 160百万 +3.6% | |
| 2020/03 | 37百万 +0.8% | 41百万 -1.3% | 40百万 -13% | 38百万 +4.6% | 155百万 -2.9% | |
| 2021/03 | 38百万 +3.6% | 40百万 -1.4% | 41百万 +3.8% | 38百万 -0.6% | 157百万 +1.3% | |
| 2022/03 | 36百万 -4.1% | 38百万 -3.9% | 45百万 +8% | 37百万 -1.9% | 157百万 -0.3% | |
| 2023/03 | 36百万 -0.6% | 39百万 +2.7% | 38百万 -15.7% | 39百万 +4.9% | 152百万 -2.8% | |
| 2024/03 | 39百万 +6.5% | 39百万 -2.4% | 39百万 +3% | 39百万 -0.2% | 155百万 +1.6% | |
| 2025/03 | 37百万 -4.4% | 39百万 +0.6% | 48百万 +24.5% | 37百万 -5.4% | 161百万 +3.8% | |
| 2026/03 | 38百万 +4.3% | 38百万 -0.9% | 36百万 -24.7% | 38百万 +2.6% | 151百万 -6.1% | |
| 営業利益 1Q2Q 3Q | 2014/03 | 57百万 | 19百万 | 41百万 | 56百万 | 173百万 |
| 2015/03 | 61百万 +6.6% | 62百万 +231.2% | 62百万 +52.4% | 49百万 -13.5% | 234百万 +35.2% | |
| 2016/03 | 63百万 +3.3% | 55百万 -10.5% | 63百万 +1.6% | 59百万 +20.8% | 240百万 +2.8% | |
| 2017/03 | 60百万 -4.8% | 59百万 +6.8% | 69百万 +8.6% | 58百万 -1% | 246百万 +2.3% | |
| 2018/03 | 59百万 -1.6% | 65百万 +10.5% | 71百万 +2.7% | 57百万 -2.3% | 252百万 +2.3% | |
| 2019/03 | 58百万 -1.6% | 69百万 +5% | 50百万 -29.2% | 63百万 +10.9% | 240百万 -4.8% | |
| 2020/03 | 57百万 -1.9% | 66百万 -4.4% | 61百万 +20.8% | 66百万 +4.5% | 249百万 +3.8% | |
| 2021/03 | 67百万 +17.2% | 66百万 +0.5% | 64百万 +6.3% | 66百万 -0.3% | 262百万 +5.5% | |
| 2022/03 | 69百万 +3% | 60百万 -9.1% | 70百万 +9% | 62百万 -4.8% | 261百万 -0.5% | |
| 2023/03 | 58百万 -15.4% | 58百万 -2.4% | 63百万 -10% | 63百万 +0.5% | 242百万 -7.2% | |
| 2024/03 | 64百万 +10.9% | 60百万 +2.2% | 65百万 +2.6% | 62百万 -0.4% | 251百万 +3.7% | |
| 2025/03 | 63百万 -2.3% | 55百万 -7.2% | 65百万 ±-0% | 61百万 -2.8% | 244百万 -3% | |
| 2026/03 | 54百万 -13.8% | 34百万 -38% | 56百万 -13.7% | 57百万 -6.7% | 201百万 -17.5% | |
| 営業利益率 | 2014/03 | 100.9% | 46.9% | 93.4% | 154.8% | 97.9% |
| 2015/03 | 162.2% +61.3% | 147.6% +100.7% | 156.4% +63% | 126.2% -28.6% | 148.1% +50.2% | |
| 2016/03 | 152.1% -10.1% | 148% +0.4% | 158.1% +1.7% | 174.5% +48.3% | 157.6% +9.5% | |
| 2017/03 | 176.5% +24.4% | 165.7% +17.7% | 183.7% +25.6% | 166.1% -8.4% | 173.1% +15.5% | |
| 2018/03 | 160.9% -15.6% | 163.4% -2.3% | 176.6% -7.1% | 151.4% -14.7% | 163.3% -9.8% | |
| 2019/03 | 159.1% -1.8% | 167% +3.6% | 109.3% -67.3% | 173.4% +22% | 150.1% -13.2% | |
| 2020/03 | 154.9% -4.2% | 161.7% -5.3% | 151.9% +42.6% | 173.3% -0.1% | 160.4% +10.3% | |
| 2021/03 | 175.2% +20.3% | 164.7% +3% | 155.5% +3.6% | 173.7% +0.4% | 167% +6.6% | |
| 2022/03 | 188.3% +13.1% | 155.8% -8.9% | 156.9% +1.4% | 168.5% -5.2% | 166.7% -0.3% | |
| 2023/03 | 160.2% -28.1% | 148% -7.8% | 167.6% +10.7% | 161.4% -7.1% | 159.1% -7.6% | |
| 2024/03 | 166.9% +6.7% | 154.9% +6.9% | 166.8% -0.8% | 161% -0.4% | 162.4% +3.3% | |
| 2025/03 | 170.6% +3.7% | 142.9% -12% | 133.9% -32.9% | 165.5% +4.5% | 151.7% -10.7% | |
| 2026/03 | 140.9% -29.7% | 89.3% -53.6% | 153.5% +19.6% | 150.5% -15% | 133.2% -18.5% | |
10年以上蓄積したファイナンスデータとAIを掛け合わせて、投資の意思決定を加速させるポジションです。
